Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Goldman on Pfizer (PFE) Post Metsera (MTSR) Deal: 'previously emphasized the importance of growing its footprint in internal medicines and primary care'
September 22, 2025 10:27 AM EDTGoldman Sachs analyst Asad Haider reiterated a Neutral rating and $27.00 price target on Pfizer (NYSE: PFE).
The analyst comments "This morning PFE announced plans to acquire Metsera (MTSR), a development stage obesity-focused biotech company with a portfolio of candidates (injectable and oral... More
Wolfe Research Comments on Path Forward for Pfizer (PFE) and Metsera (MTSR)
September 22, 2025 9:45 AM EDTWolfe Research analyst Alexandria Hammond reiterated an Underperform rating and $25.00 price target on Pfizer (NYSE: PFE).
The analyst comments "The path forward for Pfizer and Metsera. Topline data from VESPER-1 and interim data from VESPER-3 for MET-097i remain expected by the end of the month. It is our understanding,... More
